Cresco Labs (CRLBF) EBITDA (2020 - 2026)

Cresco Labs has reported EBITDA for 7 years, with the latest figure at -$17.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 13.09% year-over-year to -$17.2 million; the trailing twelve-month figure through Mar 2026 stood at -$141.4 million (down 60.04% YoY), and the FY2025 full-year result was -$139.4 million, down 84.65% from the prior year.
• EBITDA for Q1 2026 stood at -$17.2 million, up from -$88.8 million in the prior quarter.
• The five-year high for EBITDA was $27.1 million in Q4 2023, with the low at -$143.5 million in Q4 2022.
• Historically, EBITDA has averaged -$23.8 million across 5 years, with a median of -$13.3 million in 2025.
• Annual changes were most pronounced in 2022 — EBITDA sank 1022.28% — and 2023, when it surged 118.89%.
• Cresco Labs' EBITDA stood at -$143.5 million in 2022, then surged by 118.89% to $27.1 million in 2023, then plunged by 152.81% to -$14.3 million in 2024, then tumbled by 520.15% to -$88.8 million in 2025, then soared by 80.61% to -$17.2 million in 2026.
• The last three EBITDA figures came in at -$17.2 million (Q1 2026), -$88.8 million (Q4 2025), and -$22.2 million (Q3 2025), per Business Quant data.